Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Early trial of experimental cancer combo halted after just 6 patients

NCT ID NCT06870487

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new drug called PF-08046032, given alone or with another drug (sasanlimab), in adults with advanced lymphomas or solid tumors like lung cancer and melanoma. The trial aimed to check safety and find the right dose, but it was terminated early after enrolling only 6 participants. Because it was stopped, we have very limited information on how well it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PF-08046032 (a new drug given by IV) and sasanlimab (an immunotherapy given as a shot)
What this could lead to
If it works, this could point toward a new treatment option for certain advanced cancers that have not responded to standard therapies.
What could go wrong
This was a very early Phase 1 trial with only 6 participants and was terminated early, so results are limited. The drug may not prove safe or effective in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

6 people

The number who actually took part.

Started

May 2025

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA: 1. Histological or cytological diagnosis of metastatic or unresectable malignancy: * Part A1: Participants with lymphomas (cHL, PTCL, large B-cell lymphoma) who have progressed on/after standard therapies * Part A2: Participants with solid tumors (NSCLC, HNSCC, melanoma, or other limited tumor types) who have progressed on or following prior immune checkpoint inhibitor if indicated and available * Part B: Participants with solid tumors who have either progressed on/after prior immune checkpoint inhibitor, or who have not received prior immune checkpoint inhibitor therapy * Part C: Participants with selected tumor type who have not received systemic anticancer treatment for the tumor type (including prior immune checkpoint inhibitor 2. Measurable disease as defined by Lugano Classification for lymphomas or RECIST 1.1 for solid tumors 3. Able to provide tumor tissue(s) as defined by the protocol depending on the Part of the study at enrollment 4. ECOG Performance Status score 0 or 1 EXCLUSION CRITERIA: 1. Ongoing peripheral neuropathy 2. History of significant immune-mediated adverse event considered related to prior immune-modulatory therapy 3. Known or suspected active autoimmune disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Classical Hodgkin lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma diffuse large B-cell lymphoma Head and Neck Neoplasms head and neck squamous cell carcinoma hematopoietic and lymphoid system neoplasm Hodgkins lymphoma lung neoplasm mature T-cell and NK-cell non-Hodgkin lymphoma melanoma neoplasm Neoplasm Metastasis non-Hodgkin lymphoma non-small cell lung carcinoma skin neoplasm Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Classical Hodgkin lymphoma Diffuse large B-cell lymphoma Head and neck squamous cell carcinoma Melanoma Non-small cell lung cancer Peripheral T-cell lymphoma

Contacts and locations

Locations

  • Fred Hutchinson Cancer Center.

    Seattle, Washington, 98109, United States

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, 28040, Spain

  • NEXT Oncology

    San Antonio, Texas, 78229, United States

  • University of Washington Medical Center- Montlake

    Seattle, Washington, 98195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.